Confusion over booster and third Covid vaccine could be putting patients in 'harm's way'
VULNERABLE patients could be slipping through the net ahead of a nasty winter as confusion mounts over the difference between the third Covid vaccine and the booster shot, warns blood cancer charity Myeloma UK. What are the differences between the two and why is the confusion posing a grave health risk to patients? (Source: Daily Express - Health)
Source: Daily Express - Health - October 8, 2021 Category: Consumer Health News Source Type: news

ClonoSEQ minimal residual disease testing in multiple myeloma patients saves costs in Germany
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Sharing Mayo Clinic: "Divine design" gives multiple myeloma patient transplant, care at home
Ann Arneson describes her journey to Mayo Clinic as “divine design.” Ann — a retired teacher, a leader in her church and ministry, mother, grandmother, and line dance enthusiast — is Mayo Clinic’s first bone marrow transplant patient to recover at home thanks to the new advanced care at home program. “I know that people and circumstances are not by chance, but for a purpose — part of a bigger plan,” says Ann. A brush… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 5, 2021 Category: Databases & Libraries Source Type: news

Dr Reddy's launches cancer drug in Canada
"Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada's Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population," Vinod Ramachandran, Vice President and General Manager, Dr. Reddy's Laboratories Canada said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 2, 2021 Category: Pharmaceuticals Source Type: news

Blood cancer symptoms: The sign when you sleep that could signal the deadly disease
THERE are myriad symptoms to look out for when detecting the early stages of blood cancer. These indications differ when determining the nature of blood cancer, whether it is lymphoma, leukaemia myeloma, MDS, MPN or any other classification. However, recent studies have discovered an emerging symptom to look out for during the night. (Source: Daily Express - Health)
Source: Daily Express - Health - August 31, 2021 Category: Consumer Health News Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
SAN DIEGO, Aug. 30, 2021 -- (Healthcare Sales & Marketing Network) -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutic... Biopharmaceuticals, Oncology, FDA Poseida Therapeutics, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 30, 2021 Category: Pharmaceuticals Source Type: news

Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
Chimeric antigen receptor (CAR)–modified T cell therapy is effective in treating lymphomas, leukemias, and multiple myeloma in which the tumor cells express high amounts of target antigen. However, achieving durable remission for these hematological malignancies and extending CAR T cell therapy to patients with solid tumors will require receptors that can recognize and eliminate tumor cells with a low density of target antigen. Although CARs were designed to mimic T cell receptor (TCR) signaling, TCRs are at least 100-fold more sensitive to antigen. To design a CAR with improved antigen sensitivity, we directly compa...
Source: Signal Transduction Knowledge Environment - August 24, 2021 Category: Science Authors: Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., Whiteaker, J. R., Gottardo, R., Veatch, S. L., Paulovich, A. G., Riddell, S. R. Tags: STKE Research Articles Source Type: news

Different IV Bisphosphonates Tied to Similar Skeletal Event Rate Different IV Bisphosphonates Tied to Similar Skeletal Event Rate
The risk of recurrent skeletal-related events in patients with multiple myeloma is similar with IV bisphosphonate dosing schedules ranging from 4 weeks to longer than 12 weeks, a new study suggests.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - August 2, 2021 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news

Thousands of NHS patients with myeloma to be offered pill that blocks production of the blood cancer
The drug will be offered to patients shortly after diagnosis, doubling the average time the cancer takes to return, according to stunning new results from British medical trials. (Source: the Mail online | Health)
Source: the Mail online | Health - July 31, 2021 Category: Consumer Health News Source Type: news

FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma FDA Warns of Higher Death Risk With Pepaxto in Multiple Myeloma
Following an accelerated approval earlier this year, analysis of data from an ongoing confirmatory trial has shown an increased risk of death with melphalan flufenamide (Pepaxto).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Racial Disparities Persist in Multiple Myeloma Care, Outcomes
Hispanics have higher MM - related in - hospital mortality; recent decline seen in in - hospital mortality for all except NH - Blacks (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 26, 2021 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Racial Disparities Persist in Multiple Myeloma Care, Outcomes
MONDAY, July 26, 2021 -- There are persistent disparities in multiple myeloma (MM) care for non-Hispanic (NH)-Blacks and Hispanics compared with NH-Whites, according to a study published online July 18 in Leukemia& Lymphoma. Samer Al Hadidi,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2021 Category: Pharmaceuticals Source Type: news

Risk for Psoriasis Increased for Cancer Survivors
Increased risks seen for survivors of leukemia, lymphoma, multiple myeloma, skin cancer, and lung cancer in subgroup analyses (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 21, 2021 Category: Cancer & Oncology Tags: Dermatology, Internal Medicine, Oncology, Journal, Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone HORSHAM, Pa., July 12, 2021 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Co... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, DARZALEX FASPRO®, daratumumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2021 Category: Pharmaceuticals Source Type: news

FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 12, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Study: Medicare pays average of $185K per patient to treat multiple myeloma
Medicare beneficiaries with multiple myeloma incur an average of nearly $185,000 in costs billed to the government-run plan for their diagnosis and treatment, according to an analysis published Friday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 9, 2021 Category: Consumer Health News Source Type: news

Multiple Myeloma Highlights From EHA 2021 Multiple Myeloma Highlights From EHA 2021
Prof Pieter Sonneveld discusses the latest advances in multiple myeloma from EHA 2021, including novel immune approaches, management of newly diagnosed disease, and options for high-risk patients.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2021 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

Multiple Myeloma Patients May Not Mount Adequate Response to COVID Vaccine Multiple Myeloma Patients May Not Mount Adequate Response to COVID Vaccine
Patients with multiple myeloma mount a highly variable antibody response after completing the recommended two-dose COVID-19 vaccination regimen, with some not having any detectable response, according to a new study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 6, 2021 Category: Infectious Diseases Tags: Hematology-Oncology News Source Type: news

Response to COVID - 19 Vaccine Variable in Multiple Myeloma Patients
Considerable variation seen in magnitude of antibody response, from 5 to 7,882 AU/mL, following two doses of mRNA COVID - 19 vaccine (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 2, 2021 Category: Cancer & Oncology Tags: Infections, Internal Medicine, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Response to COVID-19 Vaccine Variable in Multiple Myeloma Patients
FRIDAY, July 2, 2021 -- Patients with multiple myeloma (MM) mount a highly variable antibody response after receipt of a two-dose mRNA COVID-19 vaccination regimen, according to a study published online June 28 in Cancer Cell. Oliver Van Oekelen,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 2, 2021 Category: Pharmaceuticals Source Type: news

Ga-68 PSMA-11 improves outcomes in prostate cancer patients
PET with a gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA)-11 radiotrace...Read more on AuntMinnie.comRelated Reading: Lantheus gets FDA nod for Pylarify PET agent for prostate cancer Hoag launches PET trials for prostate cancer, myeloma Novel radiotracer shows promise for prostate imaging FDA makes history with approval of Ga-68 PSMA-11 PET Point Biopharma to use Lantheus' PyL in clinical trial (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 2, 2021 Category: Radiology Source Type: news

Ex-Pentagon Chief Rumsfeld Dies of Multiple Myeloma Ex-Pentagon Chief Rumsfeld Dies of Multiple Myeloma
Rumsfeld, 88, led the Pentagon for presidents Gerald Ford and George W. Bush and was one of most influential government leaders of the first decade of the 21st century. He died at his home in Taos, NM.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Daratumumab + chemotherapy for newly diagnosed, transplant-ineligible multiple myeloma: survival benefits at acceptable cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news

Some Myeloma Patients Get No Protection From COVID - 19 Vaccines
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 30, 2021 Category: Cancer & Oncology Tags: Infections, Oncology, Pediatrics, Immunology, News, Source Type: news

Some Myeloma Patients Get No Protection From COVID-19 Vaccines
WEDNESDAY, June 30, 2021 -- Because they're often given drugs that suppress their immune systems, people battling a blood cancer known as multiple myeloma have varying responses to the COVID-19 vaccine, new research shows. Some patients had no... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 30, 2021 Category: General Medicine Source Type: news

GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer responds to standard chemotherapy. In a phase I clinical trial at Memorial Sloan Kettering Cancer Center, the galinpepimut-S vaccine, also known as GPS, has produced an impressive, anti-tumor synergy with Opdivo, based upon early data. GPS targets the WT1 protein, which is expressed in high levels of various cancers but rarely seen in normal adult cells. The protein has been especially resistant to standard chemotherapy. The vaccine works by inducing a powerfu...
Source: Asbestos and Mesothelioma News - June 29, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

EMA Panel OKs Two New Drugs for Blood Cancers EMA Panel OKs Two New Drugs for Blood Cancers
The CHMP has recommended conditional marketing authorization for idecabtagene vicleucel for multiple myeloma and tafasitamab for lymphoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Response to COVID-19 vaccines varies widely in blood cancer patients
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines--in some cases, no detectable response--pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published in Cancer Cell in June. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic researchers study potential new CAR-T cell therapy for multiple myeloma
(Mayo Clinic) Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2021 Category: International Medicine & Public Health Source Type: news

Mayo Clinic researchers study potential new CAR-T cell therapy for multiple myeloma
ROCHESTER, Minn. -- Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet."CAR-T cell therapy is a type of immunotherapy that involves harnessing the power of a person's own immune system by [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - June 25, 2021 Category: Hospital Management Source Type: news

Mayo Clinic researchers study new class of drugs to treat multiple myeloma
PHOENIX --?Mayo Clinic researchers are studying a new class of immunotherapy drugs called "bispecific antibodies" that have demonstrated potent tumor-killing activity in multiple myeloma. A paper highlighting this work was published in Blood Cancer Discovery. "CAR-T (chimeric antigen receptor-T cell therapy) cell therapy, which uses a patient's own modified immune cells to kill cancerous tumors, [...] (Source: Mayo Clinic Arizona News)
Source: Mayo Clinic Arizona News - June 14, 2021 Category: Hospital Management Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves isatuximab-irfc for multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma
Hematology / Oncology News (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

How Long Can You Live Multiple Myeloma Diagnosis
How Long Can You Live After a Multiple Myeloma Diagnosis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 11, 2021 Category: General Medicine Source Type: news

What Is Most Common Treatment for Multiple Myeloma
What Is the Most Common Treatment for Multiple Myeloma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 10, 2021 Category: General Medicine Source Type: news

What Are the Three Stages of Multiple Myeloma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 9, 2021 Category: General Medicine Source Type: news

Is Multiple Myeloma Always Fatal
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 4, 2021 Category: General Medicine Source Type: news

UC San Diego Health begins treating multiple myeloma with CAR T-cell therapy
(University of California - San Diego) As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Can a Routine Cancer Scan Flag Depression? Can a Routine Cancer Scan Flag Depression?
Whole-body imaging used routinely in cases of multiple myeloma could also flag patients with possible depression, say researchers. Maybe one day, says an expert, but not yet.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 2, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
U.S. Milestone Follows European Medicines Agency PRIME Designation for this BCMA Bispecific Antibody for the Treatment of Relapsed or Refractory Multiple Myeloma RARITAN, N.J., June 1, 2021 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharm... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, teclistamab, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 1, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors, follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. Today’s BTD marks the 11th received by Janssen’s ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlight...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news